Yoshinori Kikuchi, Hideaki Shimada, Fumiyuki Yamasaki, Taku Yamashita, Koji Araki, Kohei Horimoto, Satoshi Yajima, Masakazu Yashiro, Keigo Yokoi, Haruhiko Cho, et al. Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2. International journal of clinical oncology. 2024. 29. 5. 512-534
Sivasundaram Karnan, Ichiro Hanamura, Akinobu Ota, Lam Quang Vu, Kaori Uchino, Tomohiro Horio, Satsuki Murakami, Shohei Mizuno, Md Lutfur Rahman, Md Wahiduzzaman, et al. ARK5 enhances cell survival associated with mitochondrial morphological dynamics from fusion to fission in human multiple myeloma cells. Cell death discovery. 2024. 10. 1. 56-56
Michinori Ogura, Kazuhito Yamamoto, Yasuo Morishima, Masashi Wakabayashi, Kensei Tobinai, Kiyoshi Ando, Naokuni Uike, Mitsutoshi Kurosawa, Hiroshi Gomyo, Masafumi Taniwaki, et al. Long-term follow-up after R-High CHOP/CHASER/LEED with Auto-PBSCT in untreated mantle cell lymphoma-Final analysis of JCOG0406. Cancer science. 2023. 114. 8. 3461-3465
Sivasundaram Karnan, Akinobu Ota, Hideki Murakami, Md. Lutfur Rahman, Md Wahiduzzaman, Muhammad Nazmul Hasan, Lam Quang Vu, Ichiro Hanamura, Akihito Inoko, Miho Riku, et al. CAMK2D: a novel molecular target for BAP1-deficient malignant mesothelioma. Cell Death Discovery. 2023. 9. 1. 257-257
Hiroyuki Takamatsu, Tomohiro Matsuda, Shohei Mizuno, Tsutomu Takahashi, Shin-Ichi Fuchida, Ichiro Hanamura, Keisuke Kataoka, Nobuhiro Tsukada, Morio Matsumoto, Akira Hangaishi, et al. Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs. Haematologica. 2023. 108. 12. 3399-3408
花村 一朗. ハイリスク骨髄腫の分子病態と治療 ハイリスク染色体異常を持つ骨髄腫の分子病態と治療アプローチ(Molecular pathogenesis and treatment of high-risk myeloma Molecular pathogenesis and treatment approach of myeloma with high-risk cytogenetics). International Journal of Myeloma. 2023. 13. 3. 80-80